

---

## Product Data Sheet

---

Product Name: Erythromycin thiocyanate

Cat. No.: GC67842

### Chemical Properties

Cas. No. 7704-67-8

Formula  $C_{38}H_{68}N_2O_{13}S$

M.Wt 793.02

Solubility DMSO : 100 mg/mL (126.10 mM; Need ultrasonic)

Storage Store at -20°C, away from moisture

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

Erythromycin thiocyanate is a macrolide **Antibiotic** produced by *actinomycete Streptomyces erythreus* with a broad spectrum of antimicrobial activity. Erythromycin thiocyanate binds to bacterial 50S ribosomal subunits and inhibits **RNA-dependent protein synthesis** by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid<sup>[1][2]</sup>. Erythromycin thiocyanate also exhibits antitumor and neuroprotective effect in different fields of research<sup>[3][4]</sup>.

Erythromycin thiocyanate inhibits growth of *P. falciparum* with IC<sub>50</sub> and IC<sub>90</sub> values of 58.2 μM and 104.0 μM, respectively<sup>[1]</sup>.

Erythromycin thiocyanate (10 μM, 100 μM; 24 h, 72 h) shows antioxidant and anti-inflammatory effects and suppresses the accumulation of 4-HNE (p<0.01) and 8-OHdG (p<0.01), reduces Iba-1 (p<0.01) and TNF-α (p<0.01) expression significantly<sup>[4]</sup>.

Cell Viability Assay<sup>[4]</sup>

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

Cell Line: Embryos primary cortical neuron (from the cerebral cortices of 17-day-old Sprague-Dawley rat)

Concentration: 10, 100  $\mu$ M

Incubation Time: 24, 72 hours

Result: Improved the viability of cultured neuronal cells in vitro after 3 hours oxygen-glucose deprivation (OGD).

Erythromycin thiocyanate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth and prolong the survival time of mice from dose of 5 mg/kg in mice<sup>[3]</sup>. Erythromycin thiocyanate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg<sup>[3]</sup>.

Erythromycin thiocyanate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury<sup>[4]</sup>.

Animal Model: Female ddY mice (6-week-old) with EAC cells or CDF mice (6-week-old) with P388 cells<sup>[3]</sup>

Dosage: 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg

Administration: Gastric intubation; 30-120 days

Result: Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice.

Animal Model: Male Sprague-Dawley rats (8-week-old, 250-300 g)<sup>[4]</sup>

Dosage: 50 mg/kg

Administration: Subcutaneous single injection

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

Result: Reduced infarct volume and edema volume, improved neurological deficit.

[1]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89.

[2]. Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28.

[3]. Hamada K, et al. Antitumor effect of erythromycin in mice. Chemotherapy. 1995 Jan-Feb. 41(1):59-69.

[4]. Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA